S-1/A: Aptevo Therapeutics Announces Public Offering of Common Stock and Warrants to Fund Clinical Programs

Aptevo Therapeutics launches a public offering of common stock and warrants, aiming to raise capital for working capital and general corporate purposes, including the further development of its product candidates.

Summary

• Aptevo Therapeutics is undertaking a public offering consisting of common stock, pre-funded warrants, Series A warrants, and Series B warrants.
• The offering includes up to 12,987,013 shares of common stock, along with an equal number of Series A warrants and Series B warrants.
• Series A warrants allow the holder to purchase one share of common stock, while Series B warrants also allow the holder to purchase one share of common stock.
• The Series B warrants include a 'zero exercise price' option, potentially leading to the issuance of up to 194,805,195 shares of common stock if exercised in this manner.
• Pre-funded warrants are offered as an alternative to common stock for investors who would exceed ownership limits, exercisable at $0.0001 per share.
• The offering aims to raise approximately $18.3 million in net proceeds, which will be used for working capital and general corporate purposes, including the further development of Aptevo's product candidates.
• Roth Capital Partners, LLC is acting as the exclusive placement agent for the offering.
• The offering is set to terminate no later than May 15, 2025.
• Concurrently with the offering, Aptevo intends to issue Series C and Series D warrants in a private placement as consideration for a waiver of a Variable Rate Transaction prohibition.
• The exercise of the Series B warrants is contingent upon stockholder approval, which the company will seek at a special meeting.
• The company has agreed not to effect or enter into an agreement to effect any issuance of common stock or common stock equivalents (or a combination of units thereof) involving a Variable Rate Transaction from the date of the Inducement Letter until 180 days after the closing date thereof.

Sentiment

Score: 5

Explanation: The document presents a mix of positive and negative aspects. The capital raise is positive, but the potential dilution and dependence on stockholder approval temper the outlook.

Positives

• The offering aims to provide Aptevo with additional capital to fund its clinical programs and general corporate purposes.
• The 'zero exercise price' option on the Series B warrants could incentivize warrant holders to exercise, potentially increasing the company's capital base in the future (though not in cash proceeds).
• The concurrent private placement of Series C and Series D warrants provides additional consideration to existing warrant holders for waiving certain restrictions.
• The company has engaged Roth Capital Partners, LLC, as the exclusive placement agent in connection with this offering.

Negatives

• The 'zero exercise price' option on the Series B warrants could lead to significant dilution for existing shareholders.
• The company may not receive any cash proceeds from the exercise of the Series B Warrants if holders elect the zero exercise price option.
• The offering is subject to market conditions, and there is no guarantee that Aptevo will raise the full amount of capital it seeks.
• The exercise of the Series B warrants is contingent upon stockholder approval, which may not be obtained.
• There is no established public trading market for the common warrants or pre-funded warrants, and we do not expect a market to develop.

Risks

• The 'zero exercise price' option on the Series B warrants could lead to substantial dilution for existing stockholders.
• The company may not raise the amount of capital it believes is required for its business plans.
• The exercise of the Series B warrants is contingent upon stockholder approval, which may not be obtained.
• There is no public market for the common warrants or pre-funded warrants being offered by us in this offering.
• The Series A Warrants and the Series B Warrants are not exercisable until Stockholder Approval and may not have any value.
• The common warrants and pre-funded warrants are speculative in nature.
• Holders of the warrants offered hereby will have no rights as common stockholders with respect to the shares of our common stock underlying the warrants until such holders exercise their warrants and acquire our common stock, except as otherwise provided in the warrants.
• This is a reasonable best efforts offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business plans, including our near-term business plans.
• Purchasers who purchase our securities in this offering pursuant to a securities purchase agreement may have rights not available to purchasers that purchase our securities without the benefit of a securities purchase agreement.
• Resales of our common stock in the public market during this offering by our stockholders may cause the market price of our common stock to fall.
• This offering may cause the trading price of our common stock to decrease.
• We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• You will experience immediate and substantial dilution in the net tangible book value per share of the common stock you purchase. You may also experience future dilution as a result of future equity offerings.

Future Outlook

Aptevo intends to use the net proceeds from this offering for working capital and general corporate purposes, including the further development of its product candidates. The company plans to hold a special meeting of stockholders to obtain approval for the exercise of the warrants.

Industry Context

The document highlights the increasing recognition of bispecific therapeutics as potent anti-cancer agents, with sixteen new bispecific agents approved by the FDA in the last three years and a total of 125 bispecific drug candidates currently in development.

Stakeholder Impact

• Shareholders may experience dilution due to the potential issuance of a large number of shares upon warrant exercise.
• The capital raised could benefit employees through continued funding of research and development.
• Customers (patients) could benefit from the development of new therapies.
• Creditors may be impacted by the company's increased debt or equity structure.

Next Steps

• Aptevo will seek stockholder approval for the exercise of the warrants.
• The company will proceed with the public offering, subject to market conditions.
• Aptevo will use the net proceeds to fund its clinical programs and general corporate purposes.

Key Dates

Keywords

public offering, common stock, warrants, Series A warrants, Series B warrants, pre-funded warrants, Roth Capital Partners, dilution, stockholder approval, capital raise, Aptevo Therapeutics